Eli Lilly and Company Stock price

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Estimate Cboe BZX 11:46:15 2024-03-28 am EDT 5-day change 1st Jan Change
788 USD +1.26% Intraday chart for Eli Lilly and Company +2.70% +35.70%
Sales 2024 * 41.32B Sales 2025 * 51.34B Capitalization 701B
Net income 2024 * 10.89B Net income 2025 * 15.74B EV / Sales 2024 * 17.3 x
Net Debt 2024 * 14.38B Net Debt 2025 * 7.93B EV / Sales 2025 * 13.8 x
P/E ratio 2024 *
64.3 x
P/E ratio 2025 *
43.6 x
Employees 43,000
Yield 2024 *
0.67%
Yield 2025 *
0.77%
Free-Float 99.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.56%
1 week+2.17%
Current month+4.42%
1 month+3.87%
3 months+35.48%
6 months+44.54%
Current year+35.00%
More quotes
1 week
767.28
Extreme 767.28
793.67
1 month
727.62
Extreme 727.62
800.78
Current year
579.05
Extreme 579.05
800.78
1 year
334.58
Extreme 334.58
800.78
3 years
178.58
Extreme 178.5779
800.78
5 years
101.36
Extreme 101.36
800.78
10 years
57.35
Extreme 57.35
800.78
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 95-12-31
Director of Finance/CFO 51 00-12-31
President - -
Members of the board TitleAgeSince
Director/Board Member 63 21-01-24
Director/Board Member 67 09-03-31
Director/Board Member 59 04-12-31
More insiders
Date Price Change Volume
24-03-28 791.1 +1.67% 1 113 026
24-03-27 778.2 +0.42% 2,297,713
24-03-26 774.9 +0.23% 2,099,042
24-03-25 773.1 +0.33% 1,806,584
24-03-22 770.6 +0.05% 1,981,019

Delayed Quote Nyse, March 28, 2024 at 10:54 am EDT

More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
778.2 USD
Average target price
797.4 USD
Spread / Average Target
+2.47%
Consensus
  1. Stock
  2. Equities
  3. Stock Eli Lilly and Company - Nyse